ACVR1C Receptor: Potential Drug Target and Biomarker (G130399)

Target Name: ACVR1C

NCBI ID: G130399

ACVR1C Receptor: Potential Drug Target and Biomarker

The ACVR1C (Activin receptor type IC) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the activin receptor tyrosine kinase family, which is a subfamily of the TGF-β receptor tyrosine kinase family. Activin receptors are involved in cell signaling, including cell growth, differentiation, and survival. The ACVR1C receptor is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Function

The ACVR1C receptor is a type I transmembrane protein that is expressed in various tissues and cells, including neurons, astrocytes, endothelial cells, and cancer cells. It consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in cell adhesion and is known as the N-terminus. The transmembrane domain is responsible for the receptor's transmembrane characterization, and the intracellular domain is involved in the receptor's intracellular signaling.

The ACVR1C receptor is involved in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established signaling pathway that is involved in the development and maintenance of tissues and organs, including neural tissues. The ACVR1C receptor is involved in the TGF-β pathway by regulating the activity of the TGF-β receptor.

The ACVR1C receptor is also involved in the Wnt pathway, which is involved in cell signaling during development and growth. The Wnt pathway is a critical pathway that is involved in the development and maintenance of tissues and organs, including neural tissues. The ACVR1C receptor is involved in the Wnt pathway by regulating the activity of the Wnt receptor.

Drugs that target the ACVR1C receptor have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, inhibitors of the ACVR1C receptor have been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These inhibitors have been shown to slow down or stop the progression of neurodegenerative diseases, and to improve symptoms in both humans and animal models.

The ACVR1C receptor is also a potential biomarker for various diseases, including cancer. The ACVR1C receptor is often overexpressed in cancer cells, which means that the level of the ACVR1C receptor is increased in cancer cells compared to normal cells. This overexpression can lead to the development of cancer, and inhibitors of the ACVR1C receptor have been shown to be effective in detecting and treating various types of cancer.

Conclusion

The ACVR1C receptor is a protein that is involved in several signaling pathways, including the TGF-β and Wnt pathways. It is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. inhibitors of the ACVR1C receptor have been shown to be effective in treating neurodegenerative diseases and in detecting and treating various types of cancer. Further research is needed to fully understand the role of the ACVR1C receptor in cell signaling and to develop safe and effective drugs that target this receptor.

Protein Name: Activin A Receptor Type 1C

Functions: Serine/threonine protein kinase which forms a receptor complex on ligand binding. The receptor complex consisting of 2 type II and 2 type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators, SMAD2 and SMAD3. Receptor for activin AB, activin B and NODAL. Plays a role in cell differentiation, growth arrest and apoptosis

More Common Targets